The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2020 | NALIRIFOX as frontline therapy for PDAC
Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, discusses primary analysis from a Phase I/II study investigating first-line liposomal irinotecan and 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
